Helix BioPharma (HBP) Reports Institutional Shareholder Services Encourages Shareholders Vote for Management Nominees
Tweet
Share
E-mail
Helix BioPharma Corp.(NYSE: HBP) is pleased to announce that Institutional Shareholder Services has recommended that shareholders vote FOR the slate of directors nominated by management, which includes Jack M. Kay, W. Thomas Hodgson, Donald H. Segal, Ewa Don-Siemion, Wojciech M. Kwiatek and Wayne Schnarr, at the upcoming annual meeting ("AGM") on January 30, 2012.
ISS is a leading independent international corporate governance analysis and proxy voting firm. Its recommendations assist shareholders in making decisions regarding proxy voting. In their analysis, ISS stated:
"Ultimately we are not convinced that wholesale board change is warranted at this time. Furthermore, it is not obvious that the dissident nominees would be better able to create value than the current board."*
ISS also said: "No major strategic missteps are apparent. On balance, management appears to be taking steps to execute a reasonable plan. The management nominees are recently refreshed with 3 new independent candidates. In the circumstances, we are willing to give the incumbents the benefit of the doubt and believe that shareholders can give management more time to deliver on the strategy."*
"We are pleased that ISS supports our view that the current directors and management nominees are best suited to continue our work and further establish Helix as a leading developer of clinically proven, innovative cancer therapies," said Donald H. Segal, CEO and Director of Helix. "We will continue to represent the interests of ALL shareholders."
Shareholders are reminded to vote their BLUE proxy well in advance of the 10:00 a.m. (Toronto Time) January 26, 2012 proxy deadline.
ISS is a leading independent international corporate governance analysis and proxy voting firm. Its recommendations assist shareholders in making decisions regarding proxy voting. In their analysis, ISS stated:
"Ultimately we are not convinced that wholesale board change is warranted at this time. Furthermore, it is not obvious that the dissident nominees would be better able to create value than the current board."*
ISS also said: "No major strategic missteps are apparent. On balance, management appears to be taking steps to execute a reasonable plan. The management nominees are recently refreshed with 3 new independent candidates. In the circumstances, we are willing to give the incumbents the benefit of the doubt and believe that shareholders can give management more time to deliver on the strategy."*
"We are pleased that ISS supports our view that the current directors and management nominees are best suited to continue our work and further establish Helix as a leading developer of clinically proven, innovative cancer therapies," said Donald H. Segal, CEO and Director of Helix. "We will continue to represent the interests of ALL shareholders."
Shareholders are reminded to vote their BLUE proxy well in advance of the 10:00 a.m. (Toronto Time) January 26, 2012 proxy deadline.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Kimbell Royalty closes $221.2M mineral rights acquisition
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
